InnoCare Pharma Limited (SHA:688428)

Market Cap	26.40B +57.6%
Revenue (ttm)	2.37B +135.3%
Net Income	642.47M
EPS	0.38
Shares Out	n/a
PE Ratio	41.10
Forward PE	144.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,182,428
Average Volume	15,394,445
Open	29.00
Previous Close	28.90
Day's Range	28.56 - 29.55
52-Week Range	17.24 - 34.02
Beta	0.42
RSI	65.06
Earnings Date	Mar 25, 2026

About InnoCare Pharma

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thro...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 1,176
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688428